IRWD

Ironwood Pharmaceuticals (IRWD) is experiencing strong prescription demand for its primary product Linzess, with U.S. net profit share surging 72.6% year-over-year in the first half of 2026. The company raised its full-year 2026 revenue guidance to $460-$485 million, citing continued momentum from Linzess sales, recent FDA label expansion for pediatric patients, and favorable pricing dynamics. IRWD stock is trading at a valuation discount to the industry and carries a Zacks Rank #2 (Buy) rating.

Precigen (PGEN) and Ironwood Pharmaceuticals (IRWD) are biotech companies heavily dependent on single marketed drugs. Precigen's Papzimeos generated $74.6 million in revenues in H1 2026 with strong growth momentum and market exclusivity until 2032, while Ironwood's Linzess saw a 72.6% year-over-year profit surge. Precigen is rated as the better investment pick with a Zacks Rank #1 (Strong Buy) versus Ironwood's Rank #2 (Buy), offering clearer long-term growth prospects despite higher valuation multiples.